Search results: (10000)
News STADA Brings Innovative Drug for Treatment of Advanced Parkinson's Disease to Czech Republic
STADA PHARMA CZ is introducing a new system for continuous delivery of 3 active substances for the treatment of advanced stages of Parkinson's disease (PD) to the Czech market. It is one of the major innovations in the care of PD patients in the last two decades. The drug, which STADA acquired the rights to in 2020, had already been introduced in the Nordic countries where this treatment is successfully underway. In the Czech Republic, it has been fully covered since April 1, 2022.
News How does Benzalkonium Chloride and Prostaglandins Affect Meibomian Gland Epithelial Cells?
Benzalkonium chloride is commonly used in eye drops intended for glaucoma treatment due to its preservative effect. However, in recent years, it has been shown to cause damage to both superficial and deeper eye tissues and also provoke other difficulties. The study presented below examined its effect on the epithelium of the Meibomian glands.
News Definition and Classification of Chronic Kidney Disease According to KDIGO
We provide a brief overview of the definition and classification of chronic kidney disease based on the updated KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guidelines from 2012 (published in 2013).
News Inosine Pranobex in the Treatment of Cervical HPV Infections
The aim of the review article published in the journal Infection and Drug Resistance was to evaluate the available data on the potential use of inosine pranobex in the treatment of patients with a positive human papillomavirus finding in a cervical smear.
News Current Treatment Options for Multiple Myeloma
Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. Thanks to advancements in diagnostic methods, it is now understood as a collection of several cytologically distinct plasma cell malignancies. Alongside progress in diagnostics, there has also been rapid development in therapy, significantly improving survival rates for this previously very unfavorable diagnosis, especially in the last 15 years.
News What a Decade of Experience with Tapentadol Hydrochloride in Pain Treatment Has Shown
In an interview with Dr. Marek Hakl, Ph.D., from the Brno Pain Treatment Center, we focus on the role of tapentadol hydrochloride in the treatment of chronic pain. We discuss, among other things, its suitability for specific patients and the latest findings that confirm its excellent efficacy and fewer side effects compared to other opioids.
News How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?
Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral response to COVID-19 vaccination? And does the quantity of post-vaccination antibodies vary depending on the specific vaccine?
News Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF
On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the determination of the amount and conditions of reimbursement from health insurance for a drug containing micronized diosmin. The reimbursement is valid from March 1, 2022.
News How to Save a Leg from Amputation?
Feared complications in diabetics include defects in typical locations on the lower limbs. Their presence and frequent recurrences increase the risk of possible amputation of varying degrees, mainly depending on the involvement of deep structures, i.e., tendons, joint capsules, joints, and bones. How can this scenario be avoided? One answer might be HydroTherapy.
News End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma
The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA × √tPSA). It is a marker used to differentiate patients indicated for prostate biopsy, enabling prediction of cancer aggressiveness and helping to choose the optimal course of action for a particular patient. Its benefit in distinguishing aggressive prostate cancer from indolent tumors or benign lesions was already proven in 2015.
News Reference Intervals of Prostate Health Index (PHI) in Healthy Men
For more specific prostate cancer screening, apart from prostate-specific antigen (PSA), its free fraction (fPSA) and one of its precursors, [-2]proPSA (p2PSA), are used today. From these parameters, the so-called Prostate Health Index (PHI) can be calculated. However, reference intervals for these parameters in a healthy population were not known until now.
News The Patient Will Feel Comfortable Only with a Properly Chosen Absorption Aid
While before the approval of the amendment to the Public Health Insurance Act, it was possible to issue a prescription only for one type of aid firmly tied to a particular level of incontinence, now it is allowed to freely combine aids according to the individual needs of the patient. The modern market offers a wide range of aids − but how to choose a product that matches specific needs?
News Targeting HER2 is Clinically Meaningful Even with Its Low Expression
Distinguishing HER2 receptor expression status on the surface of breast cancer tumor cells as simply positive or negative is now proving insufficient. Ultimately, it can lead to the non-administration of effective targeted therapy. What do we actually know about the “gray zone” between HER2 positivity and negativity?
News Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension. Although it is an unpleasant complication, it does not – and should not – always be a reason to discontinue therapy. Fear of hypotension should not lead to not prescribing sacubitril/valsartan at all. We provide practical guidance on how to approach this clinical situation.
News Prokinetics in the Treatment of Diabetic Gastroparesis
One of the common complications of diabetes mellitus is a motility disorder of the gastrointestinal tract, which can affect any part of the digestive tube, and therefore has various forms. Among these therapeutically challenging conditions is diabetic gastroparesis, which involves impaired stomach emptying.
News Effect of Zolpidem on the Quality of Overnight Sleep in Terms of Episodic Memory Formation
Zolpidem is a non-benzodiazepine hypnotic used for the short-term treatment of insomnia in adults. Previous studies have shown that this gamma-aminobutyric acid (GABA-A) agonist stimulates the occurrence of sleep spindles during short daytime sleep, thereby enhancing episodic memory. A recently published study focused on the effect of zolpidem on memory after overnight sleep.
News What Benefits Do Modern Antidiabetics Bring to Patients in Primary Care?
How has the life of patients who now have the opportunity to treat diabetes mellitus in general practice changed? And what do the current prescription conditions for modern antidiabetics bring to their treating physicians? We discuss this and more with diabetologist MUDr. Katarína Nováková.
News Interstitial Lung Processes and Their Fibrotic Progression
Interstitial lung processes (ILPs) include more than 200 clinical units that share diffuse involvement of lung tissue and thus have similar clinical, radiological, and functional findings. However, their broad differential diagnosis is particularly problematic.
News Asthma and Prognosis of Patients with COVID-19
The impact of asthma, its severity, and treatment on the prognosis of patients infected with the SARS-CoV-2 coronavirus was examined in an observational study published this spring.
News Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
Empagliflozin entered the market as an antidiabetic drug operating on the principle of reducing glucose reabsorption by the kidneys from the urine and increasing its excretion through urine. Thanks to its very favorable impact on cardiovascular (CV) risks, it has gradually become an important part of treatment in cardiology as well. On May 1st, the long-awaited expansion of its reimbursement from public health insurance (ZP) for symptomatic heart failure with mildly reduced and preserved left ventricular ejection fraction (EF LK) will take place. It will thus be possible to improve the prognosis and quality of life for patients with this diagnosis. However, upon the availability of clinically verified therapy, another challenge arises in the form of underdiagnosis of patients with heart failure with preserved EF LK.